Wells Fargo & Company Oramed Pharmaceuticals Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 23,586 shares of ORMP stock, worth $54,247. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,586
Previous 25,086
5.98%
Holding current value
$54,247
Previous $61,000
6.56%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ORMP
# of Institutions
66Shares Held
8.11MCall Options Held
17.4KPut Options Held
19.5K-
Bml Capital Management, LLC Zionsville, IN2.64MShares$6.08 Million3.97% of portfolio
-
Murchinson Ltd. Toronto, A61.75MShares$4.03 Million2.03% of portfolio
-
Boothbay Fund Management, LLC New York, NY845KShares$1.94 Million0.06% of portfolio
-
Morgan Jess S & CO Inc366KShares$842,7222.07% of portfolio
-
Rathbones Group PLC Liverpool, X0290KShares$666,5460.0% of portfolio
About ORAMED PHARMACEUTICALS INC.
- Ticker ORMP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,827,100
- Market Cap $89.3M
- Description
- Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...